Medical Policy

Inflammatory Bowel Disease: Serologic Testing and Therapeutic Monitoring

MEDICAL POLICY NUMBER: 218

INSTRUCTIONS FOR USE: Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Company reserves the right to determine the application of medical policies and make revisions to medical policies at any time. The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

SCOPE: Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

COVERAGE CRITERIA .............................................................. 2
POLICY CROSS REFERENCES.................................................. 4
POLICY GUIDELINES............................................................... 4
REGULATORY STATUS............................................................ 5
CLINICAL EVIDENCE AND LITERATURE REVIEW ....................... 6
BILLING GUIDELINES AND CODING .................................... 15
REFERENCES........................................................................ 17
POLICY REVISION HISTORY................................................... 19
PLAN PRODUCT AND BENEFIT APPLICATION

☒ Commercial ☒ Medicaid/OHP* ☐ Medicare**

*Medicaid/OHP Members

Oregon: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

**Medicare Members

This Company policy may be applied to Medicare Plan members only when directed by a separate Medicare policy. Note that investigational services are considered “not medically necessary” for Medicare members.

COVERAGE CRITERIA

Thiopurine Methyltransferase (TPMT) Genetic Testing

I. Initial genotype testing (e.g., Prometheus TPMT Genetics) OR phenotype testing (e.g., Prometheus TPMT Enzyme) of thiopurine methyltransferase (TPMT) may be considered medically necessary prior to initiating treatment with 6-mercaptopurine or azathioprine.

II. The use of both genotype testing (e.g., Prometheus TPMT Genetics) and phenotype testing (i.e., Prometheus TPMT Enzyme) of thiopurine methyltransferase is considered not medically necessary and is not covered.

Thiopurine Therapeutic Drug Monitoring

III. The measurement of 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine nucleotide (6-MMPN) (e.g., Prometheus Thiopurine Metabolites) is considered medically necessary when at least one of the following (A. or B.) criteria are met:

   A. In patients who previously developed leukopenia or elevated liver biochemical tests while taking 6-mercaptopurine or azathioprine; or
   B. To monitor compliance and/or dosage in patients not responding to 6-mercaptopurine or azathioprine.

Fecal Calprotectin Testing

IV. Fecal calprotectin testing may be considered medically necessary for the differential diagnosis and/or management of inflammatory bowel disease.
Serological Markers for Diagnosing/Managing Inflammatory Bowel Disease

V. Testing for serological markers for the diagnosis and/or management of inflammatory bowel disease, including Crohn’s disease or ulcerative colitis, is considered **investigational and is not covered**. Tests/panels include, but are not limited to, the following (A.-H.):

A. Anti-Saccharomyces cerevisiae antibodies (ASCA)
B. Anti-glycan-associated Saccharomyces cerevisiae antibodies (gASCA)
C. Anti-neutrophilic cytoplasmic antibody (ANCA)
D. Perinuclear antineutrophil cytoplasmic autoantibodies (pANCA)
E. Anti-outer membrane porin protein C of Escherichia coli antibodies (anti-OmpC)
F. Anti-chitobioside carbohydrate antibodies (ACCA)
G. Anti-laminaribioside carbohydrate antibodies (ALCA)
H. Anti-mannobioside carbohydrate antibodies (AMCA)

NOD/CARD15 Genetic Testing

VI. NOD2/CARD15 genetic testing (e.g. 81401) for the diagnosis and management of inflammatory bowel disease is considered **investigational and is not covered**.

NUDT15 Genetic Testing

VII. NUDT15 genetic testing (e.g. 0034U) for the diagnosis and management of inflammatory bowel disease is considered **investigational and is not covered**.

Quantitative Polymerase Chain Reaction (PCR) Testing

VIII. Quantitative PCR testing (e.g. 0203U) for the diagnosis and management of inflammatory bowel disease is considered **investigational and is not covered**.

Panel Testing

IX. Combination panel testing of serologic, genetic, and inflammatory markers for the diagnosis and/or management of inflammatory bowel disease is considered **not medically necessary and is not covered**. Tests/panels include, but are not limited to, the following:

A. Prometheus IBD sgi Diagnostic
B. Prometheus Crohn’s Prognostic
C. IBS-Smart

**Note**: If a panel includes any serologic, genetic, or inflammatory marker which is not covered, the entire panel is considered not covered.

Link to [Evidence Summary](#)
POLICY CROSS REFERENCES

- Inflammatory Bowel Disease: Measurement of Antibodies to Immunosuppressive Therapies, MP237
- Coding Policy 30.0 Laboratory Panel Billing

The full Company portfolio of current Medical Policies is available online and can be accessed here.

POLICY GUIDELINES

BACKGROUND

Inflammatory Bowel Disease (IBD)

According to Hayes, “(i)nflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal (GI) tract that can be painful, debilitating, and, sometimes, life-threatening. IBD consists of two major forms—ulcerative colitis (UC) and Crohn’s disease (CD).”¹² UC involves inflammation of the large intestine (colon and rectum), which causes ulcers. CD causes inflammation and subsequent swelling and irritation to any part of the GI tract from the mouth to the anus. This swelling disrupts normal GI function, which causes diarrhea, abdominal discomfort, bleeding, pus formation, fever, and anemia. Severe cases can lead to weight loss, nutritional deficiencies, and growth failure (in children). Furthermore, both diseases have also been associated with an increased risk for colorectal cancer. “Since there is no cure for UC or CD, treatment is aimed at reducing symptoms or repairing intestinal complications.”³

Thiopurine Methyltransferase (TPMT) Genotyping and Phenotyping

TPMT is an enzyme involved in the metabolism of thiopurines (e.g., azathiopurine) used to treat inflammatory bowel disease (IBD).⁴ There can be a wide variation in TPMT enzyme activity that is genetically determined by the TPMT gene. According to Hayes, “normal levels of TPMT enzyme activity are found in 89% of people, 11% have intermediate activity and approximately 0.3% have little or no activity.”⁴ People who have intermediate or no TPMT enzyme activity cannot undergo treatment with thiopurines. Treatment in these patients could cause severe, life threatening bone marrow toxicity. Genotyping determines the TPMT gene alleles that result in intermediate or deficient levels of the TPMT enzyme. Phenotyping determines the level of TPMT enzyme activity present in red blood cells. According to the U.S. Food and Drug Administration (FDA), TPMT genotyping or phenotyping can be used to identify patients who have low or intermediate TPMT activity.⁵ ⁷

Thiopurine Metabolites

Monitoring of thiopurine metabolites is used to evaluate 6-thioguanine (6-TG) levels in patients not responding to thiopurine therapy.⁸ 6-TG levels have also been purported to correlate with therapeutic efficacy; however, this hypothesis has not been substantiated.⁹ According to UpToDate, “(l)ow or absent 6-TG levels in non-responding patients may indicate noncompliance, use of a sub-therapeutic dose of
azathioprine (AZA)/6-mercaptopurine (6-MP), or preferential metabolism to 6-methylmercaptopurine (6-MMP) instead of 6-TG (ie, 6-MP resistance).“¹⁰ Evaluation of thiopurine metabolites is also indicated for patients who had previous leukopenia or elevated liver biochemical tests.

Serologic Markers of Inflammatory Bowel Disease

According to Hayes, “(p)atients with inflammatory bowel disease (IBD) exhibit a serological response, or production of particular antibodies, to various microbial antigens and autoantigens.”¹¹,² To offer an alternative to standard IBD testing, serologic markers have been identified that can diagnose and distinguish Crohn’s disease (CD) from ulcerative colitis (UC). Research has identified several serum biomarkers, including anti-Saccharomyces cerevisiae antibody(ies) (ASCA) and perinuclear antineutrophil cytoplasmic antibody (pANCA). “The presence and level of these antibodies is determined by testing blood samples using serological assays, particularly enzyme-linked immunosorbent assays (ELISAs) and indirect immunofluorescence assays (IFAs).”¹¹,²

NOD2/CARD15 Genetic Testing

According to Hayes, “(m)ultiple genes and environmental factors are believed to play a role in CD susceptibility.”¹¹ The nucleotuide-binding oligomerization domain protein 2 (NOD2) (also known as caspase recruitment domain-containing protein 15 [CARD15]) was the first gene found to be associated with CD. Three variants in NOD2 are known to be associated with an increased risk for CD. The precise biochemical mechanism is unknown; however, it is thought that the variants in NOD2 result in an exaggerated immune response leading to chronic inflammation of the intestine.

Fecal Calprotectin Testing

Fecal calprotectin testing can be used to detect inflammation in the intestines associated with inflammatory bowel disease (IBD).¹²,¹³ Calprotectin is a calcium-binding protein that is abundant in white blood cells (i.e., neutrophils). According to Hayes, “(d)uring active intestinal inflammation, neutrophils are recruited to the inflamed intestinal mucosa, and calprotectin is excreted into the stool through several proposed mechanisms, including active secretion, cell death, and leakage of neutrophils into the intestinal lumen.”¹²,¹³ The level of fecal calprotectin correlates with the amount of white blood cells in the gut; thus making it a marker for intestinal inflammation.

REGULATORY STATUS

U.S. FOOD AND DRUG ADMINISTRATION (FDA)

Approval or clearance by the Food and Drug Administration (FDA) does not in itself establish medical necessity or serve as a basis for coverage. Therefore, this section is provided for informational purposes only.

The FDA has approved the thiopurines Imuran (azathioprine) and Purinethol (mercaptopurine) for the treatment of inflammatory bowel disease, specifically Crohn’s disease and ulcerative colitis.⁶,⁷ Regarding thiopurine methyltransferase (TPMT) genotyping and phenotyping, the FDA states the following:
“It is recommended that consideration be given to either genotype or phenotype patients for TPMT. Phenotyping and genotyping methods are commercially available. The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity. Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early drug discontinuation in these patients is advisable.”

The following is a list of fecal calprotectin tests currently approved for use by the U.S. Food and Drug Administration. This list may not be complete. Users should refer to the FDA website for a list of all currently approved diagnostics.

<table>
<thead>
<tr>
<th>Test Name</th>
<th>Manufacturer</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALPCO Calprotectin Chemiluminescence ELISA/ALPCO Easy Stool Extraction Device</td>
<td>ALPCO</td>
<td>In vitro diagnostic use as an aid in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC), and as an aid in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other clinical and laboratory findings.</td>
</tr>
<tr>
<td>Buhlmann FCAL Turbo and CALEX Cap</td>
<td>Buhlmann Laboratories</td>
<td>Aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.</td>
</tr>
<tr>
<td>Calprest, EasyCAI</td>
<td>Eurospital</td>
<td>Used as an in vitro diagnostic to aid in the diagnosis of Inflammatory Bowel Diseases (IBD, Crohn's disease and ulcerative colitis) and to differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical and laboratory findings.</td>
</tr>
<tr>
<td>Liaison Calprotectin assay (control set, calibration verifiers, buffer, device)</td>
<td>Diasorin Inc.</td>
<td>As an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome (IBS). Test results are to be used in conjunction with information obtained from the patients’ clinical evaluation and other diagnostic procedures.</td>
</tr>
<tr>
<td>Quanta Flash Calprotectin assay</td>
<td>Inova Diagnostics</td>
<td>Can aid in the diagnosis of inflammatory bowel disease (IBD) (ulcerative colitis and Crohn’s disease), and in the differentiation of IBD from irritable bowel syndrome (IBS).</td>
</tr>
</tbody>
</table>

**CLINICAL EVIDENCE AND LITERATURE REVIEW**

**EVIDENCE REVIEW**
A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of serologic testing and therapeutic monitoring for inflammatory bowel disease. Below is a summary of the available evidence identified through July 2022. Due to an extensive body of literature, the evidence supporting medical necessity of thiopurine methyltransferase genotyping and phenotyping and the measurement of thiopurine metabolites is based on the American College of Gastroenterology evidence-based clinical practice guidelines.

**Serologic Markers of Inflammatory Bowel Disease**

- In 2018 (reviewed in 2022), Hayes conducted an evidence review evaluating the clinical utility of genetic testing for inflammatory bowel disease (IBD). As of May 1, 2018, no peer-reviewed studies were identified assessing the clinical utility of genetic testing for IBD. Hayes concluded that evidence was insufficient to support the clinical utility of genetic testing for IBD in symptomatic individuals with known or suspected IBD, or in asymptomatic individuals with a family history of IBD.

- In 2017 (reviewed 2021), Hayes conducted an evidence review evaluating the analytical and clinical validity of Prometheus IBD sgi Diagnostic in distinguishing between IBD versus non-IBD and CD versus UC. No studies were identified demonstrating the analytical validity of the test. One study was identified that used the test to screen for IBD, however, as no other test of diagnostic tool was used to confirm results, no evidence of clinical validity could be inferred. Hayes assigned the test a “D2” rating (insufficient evidence).

- In 2013 (archived in 2018), Hayes conducted an evidence review to evaluate serological assays for the diagnosis and management of inflammatory bowel disease—Crohn's disease (CD). The evidence review identified 22 studies (18 case-control design, 1 cross-sectional design, 1 pre-post design, and 2 were performed in parallel with randomized controlled trials) as eligible for inclusion, including 4,650 patients with CD, 2,138 patients with ulcerative colitis, 117 patients with indeterminate colitis, 564 patients with gastrointestinal diseases, and 1,671 health controls. The outcomes of interest in the selected studies were measures of diagnostic performance (sensitivity, specificity, positive predictive value [PPV], and negative predictive value [NPV]). No studies evaluated the clinical utility of serological markers for UC. Findings from this body of evidence suggested that serological assays for UC have high specificity (typically ≥85%); however, “the sensitivity of assays with these serological antibodies is too low (typically ≤65%) to be effective for identifying the disease in question.” There was also limited evidence that serological antibodies (individually or in combination) can predict disease phenotype or progression. “Furthermore, there is limited evidence regarding the use of serological antibodies for predicting response to treatment.” There was also no evidence that serological testing improves patient management or health outcomes for patients with UC.

The body of evidence was determined to be of low quality. There is a high risk of bias due to the majority of studies being of cross-sectional, retrospective design. Hayes also indicated there is potential for inflated estimates of accuracy due to a “high pretest probability of the disease since the patients were already diagnosed with UC or CD upon enrollment into the study.” Furthermore, there is a lack of generalizability of these results since most of the studies were performed in Caucasian populations. Other limitations included, lack of reporting regarding...
blinding status, reporting of test sensitivity and specificity in subsets of patients rather than all patients combined, and failure to specify the statistical analysis used.

Hayes assigned the following ratings:

- **C (potential but unproven benefit)** - For serological assays using a combination of antibodies (ASCA, gASCA, pANCA combined with anti-OmpC, ACCA, ALCA, AMCA, anti-C, and/or anti-L) as an adjunct to conventional diagnostic techniques in patients with suspected CD and to aid in classifying patients with indeterminate colitis. This rating reflects the evidence suggesting that these assays may provide confirmation for a CD diagnosis, the low quality of that evidence, the uncertainty regarding the optimal combination of antibodies, and the lack of evidence demonstrating a positive impact on patient management or outcomes.

- **D1 (no proven benefit)** - For serological assays using a combination of antibodies (ASCA, gASCA, pANCA combined with anti-OmpC, ACCA, ALCA, AMCA, anti-C, and/or anti-L) for population screening of CD in asymptomatic individuals. This rating reflects the evidence of low sensitivity of these assays for CD, which indicates they produce a relatively high percentage of false negative results.

- **D2 (insufficient evidence)** - For serological assays using a combination of antibodies (ASCA, gASCA, pANCA combined with anti-OmpC, ACCA, ALCA, AMCA, anti-C, and/or anti-L) to predict disease phenotype, disease progression, or response to treatment for patients with CD. This rating reflects the low-quality and/or limited evidence for these indications as well as the lack of studies evaluating the impact of assay results on patient management or outcomes.

- **In 2013 (archived in 2018)**, Hayes conducted an evidence review to evaluate serologic assays for the diagnosis and management of inflammatory bowel disease—ulcerative colitis (UC). The literature search identified 12 studies (8 case-control studies, 1 cross-section study, 2 case series, and 1 cohort study with a 10-year follow-up) as eligible for inclusion, including 1,951 patients with UC, 1,787 patients with Crohn’s disease (CD), 32 patients with indeterminate colitis, 188 patients with other gastrointestinal (GI) disease, and 764 health controls. The outcomes of interest in the selected studies were measures of diagnostic performance (sensitivity, specificity, positive predictive value [PPV], and negative predictive value [NPV]). No studies evaluated the clinical utility of serological markers for UC.

Findings from this body of evidence suggested that serological assays for UC have high specificity (typically ≥85%); however, “the sensitivity of assays with these serological antibodies is too low (typically ≤50%) to be effective for identifying the disease in question.” There was also limited evidence that the presence of antibodies can predict disease phenotype or the progression of UC. “Furthermore, there is limited evidence regarding the use of serological antibodies for predicting response to treatment.” There was also no evidence that serological testing improves patient management or health outcomes for patients with UC.

The body of evidence was determined to be of low quality. There is a high risk of bias due to the majority of studies being of cross-sectional, retrospective design. Hayes also indicated there is potential for inflated estimates of accuracy due to a “high pretest probability of the disease since the patients were already diagnosed with UC or CD upon enrollment into the study.” Furthermore,
there is a lack of generalizability of these results since most of the studies were performed in Caucasian populations. Other limitations included, lack of reporting regarding blinding status, reporting of test sensitivity and specificity in subsets of patients rather than all patients combined, and failure to specify the statistical analysis used.

Hayes assigned the following ratings:

- C (potential but unproven benefit) - For serological assays using perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) as an adjunct to conventional diagnostic techniques in patients with suspected ulcerative colitis (UC) and to aid in classifying patients with indeterminate colitis. This rating reflects the evidence suggesting that these assays may provide confirmation for a Crohn’s disease diagnosis, the low quality of that evidence, and the lack of evidence demonstrating a positive impact on patient management or outcomes.

- D1 (no proven benefit) - For serological assays using pANCA and ASCA for population screening of UC in asymptomatic individuals. This rating reflects the evidence of low sensitivity of these assays for UC, which indicates they produce a relatively high percentage of false-negative results.

- D2 (insufficient evidence) - For serological assays using pANCA and ASCA for predicting disease phenotype, disease progression, and/or response to treatment in patients with UC. This rating reflects the low-quality and/or limited evidence for these indications as well as the lack of studies evaluating the impact of assay results on patient management or outcomes.

- In 2017 (reviewed in 2020), Hayes conducted a genetic testing evaluation (GTE) and report of the Prometheus IBD sgi Diagnostic (Prometheus Laboratories, Inc.). The GTE review was based on the ACCE model (Analytical validity; Clinical validity; Clinical utility; and Ethical, legal, and social implications) developed by the Centers for Disease Control and Prevention (CDC). The quality of evidence was determined to be insufficient or very low to evaluate the ACCE criteria; therefore, Hayes gave a D2 (insufficient evidence) rating for the Prometheus IBD sgi Diagnostic.

**Fecal Calprotectin Testing**

- In 2021, ECRI published a systematic review evaluating the clinical utility of fecal calprotectin (FC) testing for monitoring inflammatory bowel disease (IBD). Investigators examined meta-analyses of data on >7,000 patients in diagnostic cohort studies described in systematic reviews and 2 additional clinical studies. Findings suggested that FC testing's accuracy is fair to good for identifying likelihood of relapse upon endoscopy in patients with IBD. Accuracy was fair for detecting histologic remission in patients with ulcerative colitis (UC). Investigators concluded that data were nonetheless insufficient to determine FC’s clinical utility for managing therapy. A retrospective clinical utility study reported no overall treatment changes after adopting FC testing in place of colonoscopy. Researchers called for additional prospective clinical utility studies to validate findings and determine how FC affects time to treatment, treatment success, and avoidance of unnecessary treatment. No study assessing these outcomes was identified.

- In 2021 Hayes completed an updated health technology assessment on fecal calprotectin (FC) assess for monitoring disease activity and treatment management of ulcerative colitis (UC) in adults. The literature search resulted in 2 cohort studies, 11 cross-sectional studies, and 2
case-control studies that evaluated the clinical validity of FC for monitoring UC disease activity as well as one pretest-posttest study and one RCT that evaluated the clinical utility of FC for guidance of patient management.

Findings from the body of evidence suggested that fecal calprotectin testing appears to distinguish UC in remission from mild UC in patients with no or few clinical symptoms. Fecal calprotectin testing was also found to compare similarly, or sometimes better than, other commonly used markers of disease activity. However, none of the studies evaluated whether the test results would obviate the need for colonoscopy in treatment decision making, or whether treatment changes based on test results improved health outcomes. 

may be able to monitor UC activity due to moderate-to-high diagnostic sensitivity; however, it was difficult to compare to results of many of the studies due to the use of seven different methods for measurement of UC disease activity.

The overall body of evidence was found to be large, but of low quality—primarily due to the paucity of clinical utility studies. Thirteen of the reviewed studies would have normally rated good or fair in individual study quality were would to be of poor (1) or fair (12) quality. Only two studies of clinical utility met inclusion criteria and they were rated poor or very poor in quality due to failure to meet requirements of a prior power analysis, retrospective analysis, no comparison of patient management with versus without testing, and no reporting of health outcomes after changes in patient management that were associated with testing. Additional studies to help define standardized cutoffs for interpretation of fecal calprotectin testing and to determine whether this test improves management of patients who have UC compared with clinical alternatives.

Hayes assigned the following rating:

- C (potential but unproven benefit) - For the use of fecal calprotectin (FC) testing to monitor disease activity in adult patients with ulcerative colitis (UC) in adults. This rating reflects a large body of low-quality evidence suggesting that FC testing is safe and, based on clinical validity data, may aid in the prediction of disease activity in adult patients with CD. This Rating also reflects substantial uncertainty regarding the clinical utility of FC testing to change patient management and/or improve clinical outcomes, and uncertainty regarding optimal FC cutoff levels for defining disease activity or remission.

- In 2018, Tham and colleagues conducted a systematic review and meta-analysis evaluating the use of fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease. Independent investigators systematically searched the literature through July 2017, identified eligible studies, assessed study quality, extracted data and pooled results. Primary outcomes of interest included the degree of endoscopic recurrence – quantified by the Rutgeerts score (RS) – which correlates with risk of clinical and surgical recurrence and the accuracy of FC for detection of endoscopic recurrence. In total, 9 studies were included for review, and diagnostic accuracy was calculated for FC values of 50, 100, 150 and 200 μg/g. Investigators calculated pooled diagnostic sensitivity, specificity and diagnostic odds ratio for each available FC cut-off value. Analysis indicated that the optimal diagnostic accuracy was
obtained for FC value of 150 μg/g with a pooled sensitivity of 70% (95% CI 59–81%, specificity 69% (95% CI 61–77%), and diagnostic OR 5.92 (95% CI 2.61–12.17). Investigators concluded FC to be an accurate surrogate marker of postoperative endoscopic recurrence in CD patients.

- In 2017 (reviewed in 2021), Hayes conducted an evidence review to evaluate fecal calprotectin (FC) assay for monitoring disease activity in Crohn’s disease (CD). The literature search identified 16 studies (15 prospective cohort studies, 1 retrospective cross-sectional study) as eligible for inclusion, including 78 to 221 patients diagnosed with CD. Follow-up times varied from 0 to 20 months. The outcome measures included clinical validity (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV], accuracy, area under the receiver operating characteristic curve [AUROC]) and clinical utility (change in patient management or health outcomes).

Findings from the body of evidence suggested FC testing may be able to monitor CD activity due to moderate-to-high diagnostic sensitivity; however, specificity, PPVs, and NPVs varied across studies (40% to 97% specificity, 48.5% to 98% PPV, and 40% to 96.6% NPV). Furthermore, there was no direct evidence to support the clinical utility of FC testing for monitoring disease activity in patients with CD. There was also insufficient evidence to establish definitive patient selection criteria for the use of FC testing.

The overall quality of evidence was determined to be low. “Major individual study limitations included small sample sizes; lack of blinding; no follow-up; unclear, extended, or varying lengths of time between FC stool sample collection and colonoscopy or clinical assessment; retrospective selection of optimal FC cutoff values; use of multiple techniques for the reference standard; limited reporting of other measures of clinical performance (e.g., PPV and NPV); lack of correction for multiplicity in analysis; and multiple endoscopic procedures per patient unaccounted for in the analysis.”

Hayes assigned the following ratings:

- C (potential but unproven benefit) - For the use of fecal calprotectin (FC) testing systems to predict and monitor disease activity in adult patients with Crohn disease (CD). This rating reflects a large body of low-quality evidence suggesting that FC testing is safe and, based on clinical validity data, may aid in the prediction of disease activity in adult patients with CD. This Rating also reflects substantial uncertainty regarding the clinical utility of FC testing to change patient management and/or improve clinical outcomes, and uncertainty regarding optimal FC cutoff levels for defining disease activity or remission.
- D2 (insufficient evidence) - For the use of FC testing systems to predict and monitor disease activity in children and adolescents with CD. This rating reflects the paucity of studies evaluating the use of FC testing in these patient populations.

- In 2017 (reviewed in 2021), Hayes conducted an evidence review to evaluate fecal calprotectin (FC) assay for monitoring postoperative endoscopic recurrence (PER) of Crohn’s disease (CD). The literature search identified 11 studies (8 prospective cohort studies, 2 retrospective cross-sectional studies, and 1 subgroup analysis of a randomized controlled trial) including 20 to 135 patients diagnosed with CD. Follow up times varied from 0 to 24 months. The outcome
measures included clinical validity (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV], accuracy) and clinical utility (change in patient management or health outcomes following FC testing).

This body of evidence suggested FC testing usually has high NPVs (ranging from 68% to 93%) and moderate sensitivity (ranging from 63% to 95%) for the prediction of PER in patients with CD; however, the specificity and PPV was low. The high NPVs indicate a high assurance that a negative result on an FC test indicates PER will not occur, but “additional research is needed to define uniform and optimal cutoffs for FC testing to predict and monitor PER of CD.”

Furthermore, there was no direct evidence regarding the clinical utility of FC testing and its potential impacts on patient management or health outcomes in postoperative CD patients.

Overall, the quality of evidence was determined to be low. “Major individual study limitations included small sample sizes; study design; lack of blinding; no follow-up; unclear, extended, or varying lengths time between FC stool sample collection and colonoscopy; lack of correction for multiplicity in analysis; multiple endoscopic procedures per patient unaccounted for in the analysis; and nonuniform postoperative treatment.”

Hayes assigned the following ratings:

- **C** (potential but unproven benefit) - For fecal calprotectin (FC) tests to predict and monitor postoperative endoscopic recurrence (PER) in adult patients with Crohn disease (CD) who have previously undergone ileocolic resection due to refractory disease or complications. This Rating reflects low-quality evidence suggesting that FC testing may aid in the prediction of PER in patients with CD, as well as remaining uncertainties regarding optimal FC cutoff levels for defining PER and outcomes related to clinical utility.

- **D2** (insufficient evidence) - For FC tests to predict and monitor PER in pediatric and adolescent patients with CD who have previously undergone ileocolic resection due to refractory disease or complications. This Rating reflects the paucity of studies evaluating the use of these tests in these patient populations.

### NOD2/CARD15 Genetic Testing

Several historical studies were identified that evaluated the use of NOD2/CARD15 genetic testing for the diagnosis of Crohn’s disease (CD). These studies suggested NOD2 genotyping may be predictive of an increased risk of CD; however, no studies assessed the analytical validity or clinical utility of genetic testing for CD. Present-day studies of good methodological quality are required to establish the analytical validity, clinical validity, and clinical utility of NOD2/CARD15 testing for CD.

### NUDT15 Genetic Testing

Four studies (2 meta-analysis, 1 prospective study, and 1 systematic review) examined the efficacy of genetic testing for NUDT15 for the diagnosis and management of inflammatory bowel disease; however, none of the studies assessed the clinical utility of NUDT15 TESTING.
CLINICAL PRACTICE GUIDELINES

Thiopurine Methyltransferase (TPMT) Genotyping and Phenotyping

American Gastroenterological Association (AGA)

In 2017, the AGA conditionally recommended routine TPMT testing (enzymatic activity or genotype) to guide thiopurine dosing in adult patients with IBD being started on thiopurines.\(^\text{29}\) This recommendation was made on the basis of “low quality” evidence.

American College of Gastroenterology (ACG)

The 2018 ACG Clinical Guideline: Management of Crohn’s Disease in Adults offer the following recommendations: “Thiopurine methyltransferase (TPMT) testing should be considered before initial use of azathioprine or 6-mercaptopurine to treat patients with Crohn's disease (strong recommendation, low level of evidence).”\(^\text{30}\)

Thiopurine Metabolites

American Gastroenterological Association (AGA)

In 2017, the AGA conditionally recommended reactive therapeutic drug monitoring to guide treatment changes in adults with active IBD treated with anti-TNF agents.\(^\text{29}\) The AGA made no recommendation for the use of routine proactive therapeutic drug monitoring in patients with quiescent IBD due to insufficient evidence.

American College of Gastroenterology (ACG)

The 2019 ACG evidence-based clinical practice guideline for ulcerative colitis states “the patient with nonresponse or loss of response to therapy should be assessed with therapeutic drug monitoring to identify the reason for lack of response and whether to optimize the existing therapy or to select an alternate therapy”.\(^\text{31}\) The guideline also states “there is insufficient evidence supporting a benefit for proactive therapeutic drug monitoring in all unselected patients with UC in remission”. The guideline does not specifically discuss thiopurine metabolites. ACG also had the following recommendations regarding the use of thiopurine in the treatment of ulcerative colitis:

- When infliximab is used as induction therapy for patients with moderately to severely active UC, we recommend combination therapy with a thiopurine (strong recommendation, moderate quality of evidence for azathioprine)
- Use of thiopurines for maintenance for patients with previously moderately to severely active ulcerative colitis now in remission due to corticosteroid induction or cyclosporine treatment (conditional recommendation, low quality of evidence).

The 2018 ACG Clinical Guideline: Management of Crohn’s Disease in Adults offer the following recommendations: “Thiopurines (azathioprine, 6-mercaptopurine) may be effective and should be considered in treating fistulizing Crohn's disease (198) (strong recommendation, low level of evidence).”\(^\text{30}\)
Serologic Markers of Inflammatory Bowel Disease

American College of Gastroenterology

The 2019 ACG Clinical Guideline for Ulcerative Colitis in Adults offers the following recommendations:

- We recommend against serologic antibody testing to establish or rule out a diagnosis of UC (strong recommendation, very low quality of evidence).
- We recommend against serologic antibody testing to determine the prognosis of UC (strong recommendation, very low quality of evidence).

The guideline also stated, “Serologic markers such as perinuclear antineutrophil cytoplasmic antibodies (pANCA) may be found in up to 70% of patients with UC, and combination of negative anti-Saccharomyces cerevisiae antibodies with elevated pANCA levels has been proposed to facilitate establishing a diagnosis of UC. However, the pooled sensitivity of antibody testing for diagnosis of UC is low, and such markers are not used for establishing or ruling out a diagnosis of UC. Although pANCA positivity has also been associated with treatment refractory UC, the evidence supporting this is limited, and there is currently no role for such testing to determine the likelihood of disease evolution and prognosis.”

The 2018 ACG Clinical Guideline for Management of Crohn’s Disease recommends against the use of serologic markers for diagnosing Crohn’s disease, stating, “Routine use of serologic markers of IBD to establish the diagnosis of Crohn’s disease is not indicated (Summary Statement). Because of the heterogeneous nature of IBD there has been extensive research directed toward finding immunologic markers that would assist in disease diagnosis. These studies have focused on antibodies to microbial antigens and autoantibodies (Supplementary Information online). Anti-glycan antibodies are more prevalent in CD than in ulcerative colitis but have a low sensitivity, making their use in diagnosis less helpful.”

The guideline also recommends against genetic testing as a diagnostic tool: “Genetic testing is not indicated to establish the diagnosis of Crohn’s disease (Summary Statement). Certain genetic variants are associated with different phenotypic expressions in Crohn’s disease but testing remains a research tool at this time.”

NOD2/CARD15 Genetic Testing

The 2018 ACG Clinical Guideline for Management of Crohn’s Disease recommends against the use of NOD2 for diagnosing Crohn’s disease. Authors stated that “although identification of these [NOD2] variants may identify patients who are likely to have more aggressive CD, this laboratory test has not been routinely used clinically and remains a research tool.”

Fecal Calprotectin Testing

American College of Gastroenterology (ACG)

In 2019, the ACG issued a clinical practice guideline on the management of ulcerative colitis in adults. Authors concluded that “fecal calprotectin can be used in patients with UC as a noninvasive marker of diseases activity and to assess response to therapy and relapse.”
In 2018, the ACG issued a clinical practice guideline on the management of Crohn’s disease in adults. On the basis of “moderate evidence,” the ACG issued a strong recommendation for fecal calprotectin (FC) as a “helpful test that should be considered to help differentiate between the presence of IBD from IBS.” The guideline did not address the clinical utility of FC or its impact on overall health outcomes, but did state that it “may have an adjunctive role in monitoring disease activity.”

National Institute for Health and Care Excellence (NICE)

In 2013 (updated 2017), NICE issued a guidance for fecal calprotectin (FC) diagnostic tests for IBD. The guidance recommended FC testing as an option to support clinicians with the differential diagnosis of IBD or IBS in adults with recent onset lower gastrointestinal symptoms, provided cancer is not suspected. The guidance also recommended FC testing as an option to support clinicians with the differential diagnosis of IBD or non-IBD (including IBS) in children with suspected IBD who have been referred for specialist assessment.

World Gastroenterology Organization (WGO)

In 2015, the WGO included fecal calprotectin tests in a list of “high resource level” diagnostics for distinguishing between IBD and IBS.

EVIDENCE SUMMARY

Patients with intermediate or absent thiopurine methyltransferase (TPMT) enzyme activity who undergo thiopurine therapy can develop life-threatening drug toxicity; therefore, the American College of Gastroenterology (ACG) and the U.S. Food and Drug Administration (FDA) recommend genotype or phenotype testing of TPMT prior to initiating therapy with thiopurines. The ACG also recommends fecal calprotectin testing and therapeutic drug monitoring to assess lack of response to therapy, evaluate liver enzymes, leukopenia, and evaluate patient adherence.

There is not enough evidence to support the analytic validity, clinical validity, or clinical utility of testing serologic markers for the diagnosis of inflammatory bowel disease (IBD). Further studies of good methodological quality are required to establish the reliability of these tests and assure they improve IBD management and health outcomes. In addition, the American College of Gastroenterology (ACG) does not recommend the use of antibody testing for IBD, and state that the low sensitivity of testing limit the usefulness of it as a diagnostic tool.

The evidence was insufficient to support the use of NOD2/CARD15 testing or NUDT15 genetic testing for the diagnosis of inflammatory bowel disease. Further studies of good methodological quality are required to establish the analytical validity, clinical validity, and clinical utility of these testing methodologies. Furthermore, no evidence-based clinical practice guidelines were identified that address these diagnostic tests for IBD.

BILLING GUIDELINES AND CODING
Only one genotypic (CPT code: 81401) or phenotypic (CPT codes: 82542 and 82657) assay of TPMT is considered medically necessary, per individual, per lifetime.

**Coding Policy 30.0 Laboratory Panel Billing**

Testing panels must be billed using a single code. When no specific CPT or HCPCS code exists for the panel, the provider is required to bill the panel using an unlisted code. Guidelines in the CPT book state: “Do not select a CPT code that merely approximates the service provided. If no such specific code exists, then report the service using the appropriate unlisted procedure or service code.”

Unbundling occurs when a laboratory bills separately for some or all tests analyzed as part of a panel. It is not appropriate for the provider to bill any of the tests in a panel separately as if they were performed individually. This is a misrepresentation of services performed.

<table>
<thead>
<tr>
<th>CODES*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPT</strong></td>
</tr>
<tr>
<td>0169U</td>
</tr>
<tr>
<td>0203U</td>
</tr>
<tr>
<td>0286U</td>
</tr>
<tr>
<td>81335</td>
</tr>
<tr>
<td>81401</td>
</tr>
<tr>
<td>81479</td>
</tr>
<tr>
<td>82542</td>
</tr>
<tr>
<td>82657</td>
</tr>
<tr>
<td>83993</td>
</tr>
<tr>
<td>84433</td>
</tr>
<tr>
<td>84999</td>
</tr>
<tr>
<td><strong>HCPCS</strong></td>
</tr>
</tbody>
</table>
**Coding Notes:**

- The above code list is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit.
- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.
- See the non-covered and prior authorization lists on the Company **Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website** for additional information.
- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

## REFERENCES


**POLICY REVISION HISTORY**

<table>
<thead>
<tr>
<th>DATE</th>
<th>REVISION SUMMARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/2023</td>
<td>Converted to new policy template.</td>
</tr>
</tbody>
</table>